ClinConnect ClinConnect Logo
Search / Trial NCT06489873

Lutein, Zeaxathin, and Fish Oil Supplementation

Launched by TEXAS A&M UNIVERSITY · Jul 5, 2024

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

Lutein Zeaxanthin Fish Oil Supplement Macular Pigment Macular Pigment Optical Density Cognition Age Related Macular Degeneration Cognitive Performance

ClinConnect Summary

This clinical trial is looking at whether taking a daily supplement that contains lutein, zeaxanthin, and fish oil can help improve certain health aspects in healthy adults. Specifically, the researchers want to find out if this combination can enhance eye health (measured by macular pigment optical density), boost cognitive (thinking) performance, and increase bone density over a period of six months. If you have a specific level of eye health (MPOD less than 0.43), you may see significant improvements after using the supplement.

To participate, you should be between the ages of 65 and 74, have good vision (at least 20/40 or better in each eye), and have a body mass index (BMI) between 18.5 and 30. The trial is currently recruiting participants, and you would need to take either the LZF supplement or a placebo (a dummy pill with no active ingredients) every day for six months. It's important to note that some people can't participate, such as those who are allergic to the ingredients, pregnant, or taking specific medications. If you’re interested, make sure to check if you meet the eligibility criteria!

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • \<.43 MPOD, a self-reported best-corrected vision of 20/40 or better in each eye, a BMI range of 18.5-30, and meets the inclusion criteria on the preliminary participant questionnaire.
  • Exclusion Criteria:
  • allergic to lutein, zeaxanthin, or fish oil, taking supplements with \>6 mg lutein and/or \>2 mg zeaxanthin for more than two months before study starts, MPOD between \>.43, self-reported condition of vertigo, diabetic retinopathy, retinitis pigmentosa, optic neuropathy, retinal vascular occlusions, strabismus, autoimmune disorders related to visual health, currently pregnant or trying to become pregnant, history of concussion, vegan (due to gelatin in the placebo), and/or taking neuroactive medications, such as Ritalin, Adderall, antidepressants, etc.

About Texas A&M University

Texas A&M University, a leading research institution located in College Station, Texas, is dedicated to advancing knowledge and innovation in various fields, including health sciences. As a prominent clinical trial sponsor, Texas A&M University leverages its extensive resources and expertise to conduct rigorous research aimed at improving patient outcomes and addressing critical health challenges. The university fosters collaboration among multidisciplinary teams of researchers, clinicians, and students, ensuring a comprehensive approach to clinical trials that emphasizes ethical standards, scientific integrity, and community impact. Through its commitment to advancing medical research, Texas A&M University plays a vital role in the development of novel therapies and interventions.

Locations

College Station, Texas, United States

Patients applied

0 patients applied

Trial Officials

Karen M Beathard, PhD

Principal Investigator

Texas A&M University

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported